The company sees 2026 net sales increasing between 10%-15% year-over-year, excluding 2025 net sales attributable to the Analytical Reference Standards and Services segment, driven primarily by e-commerce business and new strategic partnerships.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience Reports Q1 Results, Updates 2026 Outlook
- Niagen Bioscience price target lowered to $10 from $13 at Canaccord
- Niagen Bioscience launches Niagen Plus telehealth plarform
- Niagen Bioscience announces new partnership with Olympia Pharmaceuticals
- Niagen Bioscience collaborates with USP to establish USP monograph